Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro

被引:2
|
作者
Zhang, Yaqing [1 ,2 ]
Lv, Qi [1 ,2 ]
Qi, Feifei [1 ,2 ]
Li, Fengdi [1 ,2 ]
Deng, Ran [1 ,2 ]
Liang, Xujian [1 ,2 ]
Liu, Mingya [1 ,2 ]
Yan, Yiwei [1 ,2 ]
Bao, Linlin [1 ,2 ,3 ,4 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Lab Anim Sci, Beijing Key Lab Anim Models Emerging & Reemerging, NHC Key Lab Human Dis Comparat Med, Beijing, Peoples R China
[2] Natl Ctr Technol Innovat Anim Model, Beijing, Peoples R China
[3] Chinese Acad Med Sci CAMS, Inst Lab Anim Sci, Beijing, Peoples R China
[4] Peking Union Med Coll PUMC, Comparat Med Ctr, Beijing, Peoples R China
关键词
cross-neutralize; Omicron; replication; SARS-CoV-2;
D O I
10.1002/ame2.12302
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundNew Omicron subvariants are emerging rapidly from BA.1 to BA.4 and BA.5. Their pathogenicity has changed from that of wild-type (WH-09) and Omicron variants have over time become globally dominant. The spike proteins of BA.4 and BA.5 that serve as the target for vaccine-induced neutralizing antibodies have also changed compared to the previous subvariants, which is likely to cause immune escape and the reduction of the protective effect of the vaccine. Our study addresses the above issues and provides a basis for formulating relevant prevention and control strategies. MethodsWe collected cellular supernatant and cell lysates and measured the viral titers, viral RNA loads, and E subgenomic RNA (E sgRNA) loads in different Omicron subvariants grown in Vero E6 cells, using WH-09 and Delta variants as a reference. Additionally, we evaluated the in vitro neutralizing activity of different Omicron subvariants and compared it to the WH-09 and Delta variants using macaque sera with different types of immunity. ResultsAs the SARS-CoV-2 evolved into Omicron BA.1, the replication ability in vitro began to decrease. Then with the emergence of new subvariants, the replication ability gradually recovered and became stable in the BA.4 and BA.5 subvariants. In WH-09-inactivated vaccine sera, geometric mean titers of neutralization antibodies against different Omicron subvariants declined by 3.7 similar to 15.4-fold compared to those against WH-09. In Delta-inactivated vaccine sera, geometric mean titers of neutralization antibodies against Omicron subvariants declined by 3.1 similar to 7.4-fold compared to those against Delta. ConclusionAccording to the findings of this research, the replication efficiency of all Omicron subvariants declined compared with WH-09 and Delta variants, and was lower in BA.1 than in other Omicron subvariants. After two doses of inactivated (WH-09 or Delta) vaccine, cross-neutralizing activities against various Omicron subvariants were seen despite a decline in neutralizing titers.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [31] Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
    Hachmann, Nicole P.
    Miller, Jessica
    Collier, Ai-ris Y.
    Ventura, John D.
    Yu, Jingyou
    Rowe, Marjorie
    Bondzie, Esther A.
    Powers, Olivia
    Surve, Nehalee
    Hall, Kevin
    Barouch, Dan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01): : 86 - 88
  • [32] In Vitro Study Comparing SARS-CoV-2 Ancestral and Omicron Lineages Sequence & Neutralization Differences
    Burroughs, Ashley
    Paden, Clinton
    Mittal, Neha
    Castro, Juan
    Cook, Peter
    Lester, Sandra
    Hicks, Heather
    Tamin, Azaibi
    Dawood, Fatimah
    Decuir, Jennifer
    Surie, Diya
    Coughlin, Melissa M.
    Harcourt, Jennifer L.
    Thornburg, Natalie J.
    Atherton, Lydia J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [33] Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
    Moriyama, Miyu
    Lucas, Carolina
    Monteiro, Valter Silva
    Iwasaki, Akiko
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (16)
  • [34] Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 108
  • [35] Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
    Cho, Junhyung
    Shin, Younmin
    Yang, Jeong-Sun
    Kim, Jun Won
    Kim, Kyung-Chang
    Lee, Joo-Yeon
    ANTIVIRAL RESEARCH, 2023, 214
  • [36] Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1
    Lasrado, Ninaad
    Rossler, Annika
    Rowe, Marjorie
    Collier, Ai-ris Y.
    Barouch, Dan H.
    VACCINE, 2024, 42 (09) : 2117 - 2121
  • [37] Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
    Liu, Li-Teh
    Chiou, Shyh-Shin
    Chen, Po-Chih
    Chen, Chun-Hong
    Lin, Ping-Chang
    Tsai, Ching-Yi
    Chuang, Wan-Long
    Hwang, Shang-Jyh
    Chong, Inn-Wen
    Tsai, Jih-Jin
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [38] SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats
    Malik, Sumira
    Uniyal, Priyanka
    Bora, Jutishna
    Haque, Shafiul
    Swed, Sarya
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (02) : 94 - 95
  • [39] Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants
    Rosales, Romel
    McGovern, Briana L.
    Rodriguez, M. Luis
    Leiva-Rebollo, Rocio
    Diaz-Tapia, Randy
    Benjamin, Jared
    Rai, Devendra K.
    Cardin, Rhonda D.
    Anderson, Annaliesa S.
    Sordillo, Emilia Mia
    van Bakel, Harm
    Simon, Viviana
    Garcia-Sastre, Adolfo
    White, Kris M.
    ANTIVIRAL RESEARCH, 2024, 230
  • [40] Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
    Zou, Jing
    Xia, Hongjie
    Xie, Xuping
    Kurhade, Chaitanya
    Machado, Rafael R. G.
    Weaver, Scott C.
    Ren, Ping
    Shi, Pei-Yong
    NATURE COMMUNICATIONS, 2022, 13 (01)